• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Actelion rejects J&J’s takeover offer

December 1, 2016 By Sarah Faulkner

Actelion rejects J&J's takeover offerSwiss biotech firm Actelion Pharmaceuticals (VTX:ATLN) reportedly rejected Johnson & Johnson‘s (NYSE:JNJ) 2nd takeover offer, sending it shares down -6% in afternoon trading yesterday. The 2 companies have been engaged in informal talks for 2 months, according to Reuters, and the latest offer was pegged at 250 Swiss francs per share.

J&J’s $270 billion bid for Actelion tempted shareholders, who would rather have the cash now than wait and bet on Actelion CEO Jean-Paul Clozel’s risky pipeline of therapeutics for rare diseases, 1 investor told the news service.

“If I look at the (drugs) pipeline that Mr. Clozel is excited about, I am perhaps less excited about it and see perhaps a greater risk than reward,” Union Bancaire Privee fund manager Eleanor Taylor Jolidon told Reuters. Union Bancaire Privee is among the top 40 investors in Actelion and holds 0.23% of outstanding shares.

Jolidon said than an offer of 250 francs per share would be very enticing and that if Clozel rejected the bid, then “he would have a lot of explaining to do.”

Clozel, 1 of the firm’s co-founders, has always made efforts to keep the company independent. In 2011, he rallied shareholders against an investor’s campaign to put the firm up for sale and then rejected a takeover interest from British drugmaker Shire in 2015.

J&J was hoping for a straightforward takeover of the company, but Actelion wanted J&J to instead become a major shareholder in a new entity.

Actelion shares soared on Friday after news of the initial offer broke, up +19% to a peak of 187.70 Swiss francs, which put the company at a value of $20 billion. This week, following news that Actelion declined J&J’s 2nd offer, its shares dropped -6%. Today, ATLN shares were trading at $198.30 in mid-morning activity, up +1.2%.

Filed Under: Featured, Mergers & Acquisitions, Pharmaceuticals, Respiratory, Wall Street Beat Tagged With: Actelion Pharmaceuticals, johnsonandjohnson

IN CASE YOU MISSED IT

  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling
  • Senseonics stock is up as it sticks by revenue guidance
  • Rapid Dose closes first tranche of $5M financing

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS